A dual GLP-1/GIP receptor agonist, FDA-approved under brand names for diabetes and weight management, and widely researched at a range of doses.
Reviewed for accuracy · Last reviewed July 7, 2026Tirzepatide acts on both the GLP-1 and GIP receptors, which together slow gastric emptying, reduce appetite, and improve insulin sensitivity. It's given as a once-weekly subcutaneous injection, usually starting low and increasing every four weeks.
Because it's sold as a prefilled pen at fixed doses commercially, people sourcing it independently as a vial often need to work out unit conversions by hand. The chart below is a starting point.
The weight-management label starts at 2.5 mg once weekly and increases no sooner than every four weeks to a maximum of 15 mg. Vial users often convert milligrams to insulin-syringe units by hand.
Read the full Tirzepatide dosage guide →Adverse reactions are predominantly gastrointestinal (nausea, diarrhea, vomiting, constipation, abdominal pain), mostly mild to moderate and concentrated during dose escalation. The label carries a boxed warning for thyroid C-cell tumors.
Read the full Tirzepatide side effects guide →Keep unmixed vials refrigerated and away from light. Once reconstituted, most research reports store it refrigerated for roughly 3–4 weeks. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting or adjusting any compound.